@entity1161 ( @entity1161 ) plays a major role in the definitive treatment of @entity1 with @entity1149 who are unable to tolerate surgery. @entity1161 alone is used primarily for early-stage (stages I and II) @entity1 . Higher doses of @entity1161 (>65 Gy) seem to improve outcomes, and modern techniques such as stereotactic body @entity1161 have been very promising. For @entity1 with locally advanced disease (stages IIIA and IIIB), concurrent chemotherapy and @entity1161 remains the standard of care. However, many @entity1 cannot tolerate the regimen because of its @entity137 . Sequential chemotherapy followed by @entity1161 is used in these situations. @entity1161 alone is used for the rare @entity1 who cannot tolerate the use of any chemotherapy because of comorbid conditions. Palliative external-beam @entity1161 is useful for @entity1 with @entity3 , causing symptoms such as @entity1353 , cough, hemoptysis, @entity55 , and @entity158 . Hypofractionation has been attempted as a means to provide more rapid and convenient symptom relief, but results from clinical trials are conflicting on whether it is an improvement over standard palliative fractionation. Endobronchial brachytherapy provides relief for @entity1 with @entity75 causing obstruction or hemoptysis. Palliative chemotherapy improves survival and quality of life in @entity1 with @entity3 compared with best supportive care. Chemotherapy also improves outcomes as a second-line and third-line treatment for @entity1 in whom previous regimens have failed. Biologic therapies such as @entity3866 and bevacizumab have been incorporated into every phase of chemotherapy with good results.

ACR appropriateness criteria on nonsurgical treatment for XXXX : poor performance status or palliative intent.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity1353 :: ('MESH:D004417', 'Disease') :: ['dyspnea'] @entity1161 :: ('MESH:D011832', 'Disease') :: ['RT', 'Radiation therapy'] @entity55 :: ('MESH:D011014', 'Disease') :: ['postobstructive pneumonia'] @entity75 :: ('MESH:D001927', 'Disease') :: ['endobronchial lesions'] @entity1149 :: ('MESH:D002289', 'Disease') :: ['non-small-cell lung cancer'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastatic disease'] @entity158 :: ('MESH:D010146', 'Disease') :: ['pain'] @entity3866 :: ('MESH:C400278', 'Chemical') :: ['erlotinib']
@entity1149 :: (MESH:D002289,Disease) :: ['non-small-cell lung cancer']
